-
Toremifene Citrate: Oral SERM Workflows for Breast Cancer Re
2026-05-04
Toremifene Citrate empowers researchers with reproducible, data-driven breast cancer and estrogen receptor signaling assays. This article delivers actionable protocols, troubleshooting strategies, and comparative insights for high-impact hormone receptor modulation studies.
-
Repurposing Natural Compounds as SARS-CoV-2 3CLpro Inhibitor
2026-05-03
This study uses molecular docking and dynamics to identify natural vitamins that bind and potentially inhibit two critical SARS-CoV-2 targets: the main protease (3CLpro) and the spike protein's receptor-binding domain. The findings offer mechanistic insight into antiviral repurposing strategies relevant to COVID-19, with implications for future inhibitor development.
-
Mifepristone (RU486): Precision Tools for Cancer & Fertility
2026-05-02
Mifepristone (RU486) empowers researchers to dissect progesterone receptor signaling in oncology and reproductive biology with high specificity. This guide translates reference-driven insights into actionable workflows, troubleshooting advice, and advanced applications for tumor growth inhibition and gamete biology.
-
Demethyleneberberine (DMB): Mechanisms and Benchmarks for Tr
2026-05-02
Demethyleneberberine (DMB) is a natural isoquinoline alkaloid with well-validated anti-inflammatory and anti-cancer properties, particularly in non-small cell lung cancer (NSCLC) models. Mechanistically, DMB modulates NF-κB, MAPK, and c-Myc/HIF-1α signaling. This article provides protocol parameters, evidence, and workflow guidance for researchers integrating DMB into cell and animal studies.
-
Oridonin Inhibits TLR4/NF-κB/NLRP3 to Suppress Esophageal Ca
2026-05-01
This study demonstrates that oridonin exerts anti-cancer effects in a mouse model of esophageal cancer by inhibiting inflammation through the TLR4/NF-κB/NLRP3 inflammasome pathway. The findings highlight oridonin’s capacity to downregulate key inflammatory mediators and tumor-associated markers, advancing mechanistic understanding for anti-inflammatory strategies in esophageal cancer.
-
Tacalcitol Monohydrate: Synthetic Vitamin D3 Analog for Prec
2026-04-30
Tacalcitol monohydrate, a high-purity synthetic analog of vitamin D3, empowers dermatology and oncology research with reproducible NGF induction, gene regulation, and synergistic cancer therapy at low toxicity. This article details actionable protocols, troubleshooting strategies, and advanced applications leveraging APExBIO’s trusted product.
-
Toremifene vs Tamoxifen: Systematic Evidence in Advanced Bre
2026-04-30
A Cochrane systematic review rigorously compared Toremifene and Tamoxifen, two oral selective estrogen receptor modulators, for treating advanced breast cancer. The study provides high-confidence evidence that both agents offer similar efficacy and safety, clarifying their interchangeability in research and clinical paradigms.
-
Pharmacokinetics of Corydalis saxicola Alkaloids in MASH Mod
2026-04-29
This study provides an integrated pharmacokinetic analysis of Corydalis saxicola Bunting total alkaloids (CSBTA) in the context of metabolic dysfunction-associated steatohepatitis (MASH), with a focus on how disease state alters systemic exposure, liver distribution, and transporter/metabolic enzyme expression. The findings inform rational dosing strategies for CSBTA in MASLD/MASH and highlight the role of transporter modulation in pharmacokinetic variability.
-
GLP-1 (9-36) amide: Precision in GLP-1 Receptor Antagonism
2026-04-29
GLP-1 (9-36) amide enables targeted interrogation of GLP-1 receptor signaling with unmatched specificity, advancing type 2 diabetes and metabolic regulation research. This guide translates recent high-throughput FRET and cAMP assay breakthroughs into actionable protocols and troubleshooting pathways, ensuring reproducible and high-fidelity results for bench scientists.
-
RapaLink-1: Third-Generation mTOR Inhibitor for Dormancy Ass
2026-04-28
RapaLink-1 delivers unprecedented potency for both cancer cell growth inhibition and embryonic dormancy induction, outperforming first- and second-generation mTOR inhibitors in overcoming resistance mutations. Its dual binding mechanism and validated, noninvasive protocols empower scalable, reproducible workflows in oncology and development research.
-
Toremifene Citrate: Clinical Mechanisms and Research Implica
2026-04-28
This article examines the innovation and findings of the reference study on Toremifene Citrate, an oral selective estrogen receptor modulator (SERM) used in breast cancer treatment. The study clarifies Toremifene’s mechanistic action, clinical comparability to tamoxifen, and key considerations for research and translational applications.
-
CORE LNPs Enable Spleen-Targeted mRNA Delivery via Cholester
2026-04-27
This study introduces Cholesterol Altered Lipid Nanoparticles (CORE LNPs), which achieve selective delivery and expression of mRNA in the spleen rather than the liver after intravenous administration. By synthesizing and incorporating novel cholesterol analogs with nitrogen-based heterocycles, the authors demonstrate a rational, material-driven approach to extrahepatic mRNA targeting—opening new avenues for immunotherapy and vaccine applications.
-
Indazole/Indole Glucagon Receptor Antagonists: SAR and In Vi
2026-04-27
The reference study presents a novel series of indazole- and indole-based glucagon receptor antagonists, systematically exploring structure–activity relationships (SAR) to optimize potency and oral efficacy. These compounds, derived from the scaffold of MK 0893, demonstrate significant glucose-lowering effects in humanized mouse models, offering promising leads for type 2 diabetes research and therapeutic development.
-
Ginsenoside Rg1 Restores Gut-Brain Axis After Isoflurane Ane
2026-04-26
This study rigorously investigates Ginsenoside Rg1's capacity to counteract neuroimmune disruptions and cognitive deficits induced by prolonged isoflurane anesthesia. Employing behavioral, immunological, and gut barrier assays, the authors delineate a Treg-dependent mechanism linking gut, immune, and neural health, offering a mechanistic foundation for translational neuroprotection strategies.
-
FAPα-Sensitive Nanoparticle Probes for Solid Tumor Diagnosis
2026-04-25
Feng et al. present a nanoparticle-based urinary probe sensitive to fibroblast activation protein α (FAPα), enabling precise, noninvasive diagnosis of FAPα-positive solid tumors. Their approach demonstrates high stability, specificity, and diagnostic accuracy, offering a promising direction for tumor microenvironment-targeted biomarker strategies.